

Efforts Toward Further Growth

June 19, 2025


Impact of the OPDIVO patent cliff (patent expiration)



formulation	Global (BMS)	Japan (ONO)
Intravenous Infusion	<u>Patent expiration</u> US : 2028、 EU : 2030 ⇒ Royalty income decrease gradually	<u>Patent expiration</u> JP : 2031 ⇒ Domestic sales decrease
Subcutaneous formulation	US : launched、 EU : Approved ⇒ Royalty income for 10 years	Phase I

Significance of overseas expansion

Regional sales share※1



Regional sales share (vs. Japan)

US : More than 10 times

EU : More than 3 times

By direct sales of multiple products in the large-scale markets of the US and Europe, we will overcome the Opdivo patent cliff and achieve further growth.

※1 Source: Company analysis based on "IQVIA Analytics Link (2024)". Copyright © 2025 IQVIA. All rights reserved. Reprinted with permission

※2. Euro5: Germany, France, UK, Italy, Spain

Strengthening overseas expansion centered on Deciphera




In July 2025, integrate US and European development and sales operations into Deciphera to centralize and accelerate global market expansion.



Pipeline (Excluding OPDIVO)



As of June 19, 2025



Major progress over the past year (Pipeline)

Global

- Deciphera : launch of ROMVIMZA following QINLOCK



- Tirabrutinib (Japan Name : VELEXBRU)scheduled for US launch in 2026

- Sapablursen (Polycythemia Vera : Phase II) In-licensed

Japan

- Gel-One® (Osteoarthritis : Phase III) In-licensed (basic agreement)


- Cenobamate (Partial-onset seizures etc : Phase III) scheduled for filing in 2025

We will start Global direct sales with three products - QINLOCK, ROMVIMZA, VELEXBRU - and enhance both our global and domestic product portfolios.

Promising product candidates

Code	MOA	Target Indication	Area	Stage
ONO-4578	PG receptor (EP4) antagonist	Gastric cancer (with Opdivo)	JP · KR · TW	Phase II
		Colorectal cancer (with Opdivo)	JP · US · EU	Phase II
ONO-4685	PD-1 × CD3 bispecific antibody	T-cell lymphoma	JP · US	Phase I
ONO-2808	S1P5 receptor agonist	Multiple System Atrophy	JP · US	Phase II
ONO-0530 (Sapablursen)	Antisense oligonucleotide targeting TMPRSS6	Polycythemia Vera	US · EU · AU	Phase II
DCC-3014 (Vimseltinib)	CSF-1R inhibitor	cGVHD	US	Phase II
ONO-2020	Epigenetic Regulation	Alzheimer's Disease	JP · US	Phase II
		Agitation Associated with Dementia Due to Alzheimer's Disease	JP	Phase II
ONO-1110	Endocannabinoid regulation	Postherpetic Neuralgia, Major Depressive Disorder, Fibromyalgia, Social Anxiety Disorder, Hunner Type Interstitial Cystitis	JP	Phase II

Projection for the Next 10 years



※Diagram does not represent actual sales of each product

